TARA on Nasdaq

Proteon Therapeutics

Logo: proteontherapeutics.com⁴

American pharmaceutical company

Proteon Therapeutics, Inc. is a developer of pharmaceuticals with offices in Waltham, Massachusetts and Kansas City, Missouri.³ From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 18, 2026.

Overview

Jan 1, 2001Founded¹

Compare with DYADIC INTERNATIONAL INC, Surrozen, Inc./DE or CRISPR Therapeutics, or pick any stock.

TickerTARA on Nasdaq¹
Industrypharmaceutical industry¹
HeadquartersWaltham¹
Websitewww.proteontherapeutics.com
Business address345 Park Avenue South, 3Rd Floor, New York, Ny 10010⁵
Filer categoryNon-accelerated filer, Smaller reporting company⁵

See how the biggest companies compare on our leaderboards

Proteon Therapeutics image from its website — Image: proteontherapeutics.com⁴

Proteon Therapeutics, Inc. is a developer of pharmaceuticals with offices in Waltham, Massachusetts and Kansas City, Missouri.³

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income⁷⁸⁹¹⁰¹¹¹²-$64.5M in 2025+724% since 2019

Net income⁷⁸⁹¹⁰¹¹¹²-$57.4M in 2025+634% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.¹²

Period ending	2025-12-31	2024-12-31
Research and development	$42.6M	$31.7M
General and administrative	$21.9M	$17.4M
Total operating expenses	$64.5M	$49.2M
Income (Loss) from operations	-$64.5M	-$49.2M
Interest and investment income (expense)	$6.4M	$4.2M
Other income (expense)	$730.0K	$387.0K
Other income (expense), net	$7.1M	$4.6M
Net income (loss)	-$57.4M	-$44.6M
Net unrealized gain (loss) on marketable debt securities	$88.0K	$33.0K
Other comprehensive income (loss)	$88.0K	$33.0K
Comprehensive income (loss)	-$57.4M	-$44.6M
Net income (loss) per share attributable to common stockholders, basic (in Dollars per share)	-$1.34	-$2.17
Net income (loss) per share attributable to common stockholders, diluted (in Dollars per share)	-$1.34	-$2.17
Weighted-average shares outstanding, basic (in Shares)	42.8M shares	20.6M shares
Weighted-average shares outstanding, diluted (in Shares)	42.8M shares	20.6M shares

Total assets⁷⁸⁹¹⁰¹¹¹²$209.5M in 2025+17027% since 2019

Total liabilities⁷⁸⁹¹⁰¹¹¹²$13.1M in 2025+290% since 2019

Shareholders’ equity⁸⁹¹⁰¹¹¹²$196.4M in 2025

Cash⁷⁸⁹¹⁰¹¹¹²$49.7M in 2025+8704% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.¹²

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$49.7M	$162.8M
Marketable debt securities	$105.9M	$7.5M
Prepaid expenses and other current assets	$4.0M	$1.9M
Total current assets	$159.5M	$172.2M
Restricted cash, non-current	$745.0K	$745.0K
Marketable debt securities, non-current	$42.3M
Property and equipment, net	$759.0K	$1.0M
Operating lease right-of-use asset	$3.2M	$4.3M
Other assets	$3.0M	$3.3M
Total assets	$209.5M	$181.5M
Accounts payable	$3.5M	$4.4M
Accrued expenses and other current liabilities	$6.2M	$5.4M
Operating lease liability	$1.2M	$1.1M
Total current liabilities	$10.9M	$11.0M
Operating lease liability, non-current	$2.1M	$3.4M
Total liabilities	$13.1M	$14.3M
Common stock, $0.001 par value, authorized 100,000,000 shares: Common stock, 53,587,260 and 35,044,772 shares issued and outstanding as of December 31, 2025 and 2024, respectively.	$54.0K	$35.0K
Additional paid-in capital	$498.7M	$412.1M
Accumulated deficit	-$302.4M	-$245.0M
Accumulated other comprehensive income (loss)	$90.0K	$2.0K
Total stockholders equity	$196.4M	$167.1M	$68.3M
Total liabilities and stockholders equity	$209.5M	$181.5M
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in Shares)	10.0M shares	10.0M shares
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized (in Shares)	100.0M shares	100.0M shares
Common stock, shares issued (in Shares)	53.6M shares	35.0M shares
Common stock, shares outstanding (in Shares)	53.6M shares	35.0M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$49.7M	$162.8M
Marketable debt securities	$105.9M	$7.5M
Prepaid expenses and other current assets	$4.0M	$1.9M
Total current assets	$159.5M	$172.2M
Restricted cash, non-current	$745.0K	$745.0K
Marketable debt securities, non-current	$42.3M
Property and equipment, net	$759.0K	$1.0M
Operating lease right-of-use asset	$3.2M	$4.3M
Other assets	$3.0M	$3.3M
Total assets	$209.5M	$181.5M
Accounts payable	$3.5M	$4.4M
Accrued expenses and other current liabilities	$6.2M	$5.4M
Operating lease liability	$1.2M	$1.1M
Total current liabilities	$10.9M	$11.0M
Operating lease liability, non-current	$2.1M	$3.4M
Total liabilities	$13.1M	$14.3M
Common stock, $0.001 par value, authorized 100,000,000 shares: Common stock, 53,587,260 and 35,044,772 shares issued and outstanding as of December 31, 2025 and 2024, respectively.	$54.0K	$35.0K
Additional paid-in capital	$498.7M	$412.1M
Accumulated deficit	-$302.4M	-$245.0M
Accumulated other comprehensive income (loss)	$90.0K	$2.0K
Total stockholders equity	$196.4M	$167.1M	$68.3M
Total liabilities and stockholders equity	$209.5M	$181.5M
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in Shares)	10.0M shares	10.0M shares
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized (in Shares)	100.0M shares	100.0M shares
Common stock, shares issued (in Shares)	53.6M shares	35.0M shares
Common stock, shares outstanding (in Shares)	53.6M shares	35.0M shares

Cash from operations⁷⁸⁹¹⁰¹¹¹²-$56.4M in 2025+1025% since 2019

Capital spending⁷⁸⁹¹⁰¹¹¹²$94.0K in 2025−80% since 2019

Free cash flow⁷⁸⁹¹⁰¹¹¹²-$56.5M in 2025+929% since 2019

Share buybacks⁹¹⁰$91.0K in 2023−60% since 2021

Every line of the cash flow as filed: the last 2 fiscal years, latest first.¹²

Period ending	2025-12-31	2024-12-31
Net income (loss)	-$57.4M	-$44.6M
Stock-based compensation	$3.8M	$4.1M
Operating lease right-of-use asset	$1.1M	$1.0M
Depreciation	$362.0K	$332.0K
Realized loss (gain) on redemption of marketable debt securities	-$9.0K
Amortization of premium (Accretion of discount) on marketable debt securities	-$1.2M	-$685.0K
Prepaid expenses and other current assets	-$2.1M	$1.3M
Other assets	$322.0K	-$328.0K
Accounts payable	-$873.0K	$1.4M
Accrued expenses and other current liabilities	$821.0K	$2.7M
Operating lease liabilities	-$1.1M	-$984.0K
Net cash provided by (used in) operating activities	-$56.4M	-$35.8M
Purchase of marketable debt securities	-$204.6M	-$29.4M
Proceeds from maturity and redemption of marketable debt securities	$65.2M	$48.6M
Purchase of property and equipment	-$94.0K	-$63.0K
Net cash provided by (used in) investing activities	-$139.5M	$19.2M
Proceeds from December 2024 Public Offering, net of offering costs of $6,051		$94.0M
Proceeds from private placement, net of offering costs of $3,034		$42.0M
Proceeds from exercise of Underwriters Option in December 2024 Public Offering, net of offering costs of $214	$2.5M
Offering costs paid in connection with the December 2024 Public Offering	-$614.0K
Proceeds from December 2025 Public Offering, net of offering costs of $5,286	$81.0M
Proceeds from exercise of stock options	$21.0K	$135.0K
Taxes paid related to net share settlement of restricted stock units	-$185.0K	-$83.0K
Net cash provided by (used in) financing activities	$82.7M	$139.9M
Net increase (decrease) in cash and cash equivalents and restricted cash	-$113.1M	$123.2M
Proceeds from public offering offering costs incurred but not paid	$526.0K	$614.0K
Proceeds from public offering, net of offering costs		$6.1M
Private placement, net of offering costs of		$3.0M
Public Offering, net of offering costs	$214.0K
Public Offering, net of offering costs	$5.3M

Compare Proteon Therapeutics with another company

The story

Proteon was founded by Dr. F. Nicholas Franano based on technology created at Johns Hopkins University. Major investors in the company include MPM Capital, Rockhill Partners, TVM Capital, Skyline Ventures, Prism VentureWorks, Vectis Life Sciences and Intersouth Partners. They have invested over $72 million in the company.

The company is led by Timothy Noyes, CEO; Steven Burke, CMO; George Eldridge, CFO; and Scott Toner, director of marketing.

On March 5, 2009, the company announced that it had raised $32 million from its existing investors plus MPM Capital and Vectis Life Sciences. Proteon also announced that it had entered into an option agreement to be acquired by Novartis for up to $550 million. The company went public in 2014.

In September 2019, Proteon Therapeutics merged with ArTara Therapeutics.

From Wikipedia’s article on Proteon Therapeutics, shared under CC BY-SA 4.0.⁶

Leadership

Who has led Proteon Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

20052010201520202025

Chief executive officerJesse Shefferman Jan 13, 2020 to now¹⁵
Chief executive officerTimothy P. Noyes Oct 21, 2014 to Feb 4, 2019¹⁶
PresidentJesse Shefferman Jan 13, 2020 to now¹⁵
PresidentTimothy P. Noyes Oct 21, 2014 to Feb 4, 2019¹⁶
Chief financial officerPatrick Fabbio Jan 30, 2023 to now¹⁷
Chief financial officerBlaine Davis Feb 11, 2020 to Jul 19, 2022¹⁸

Board members and other officers (32)

Chief Medical OfficerLeonardo Viana Nicacio Apr 17, 2025 to now¹⁹
Chief Commercial OfficerWilliam Conkling Jun 4, 2025 to now²⁰
Chief Medical OfficerJathin Bandari Jan 12, 2022 to Jan 23, 2024²¹
VP, ControllerHannah Fry Jul 19, 2022 to now²²
Chief Medical OfficerMartin Sebastian Olivo Apr 20, 2021 to Jun 14, 2021²³
Sr. Vice President, ResearchJacqueline Zummo Jan 13, 2020 to now²⁴
Chief Medical OfficerJulio Casoy Jan 13, 2020 to Jan 13, 2020²⁵
VP, PeopleBradley J. Hartman Aug 2, 2018 to Jan 23, 2019²⁶
VP, Legal and SecretaryMatthew Paul Kowalsky May 5, 2017 to Jan 23, 2019²⁷
Senior VP of MarketingE. Scott Toner Jun 3, 2015 to Jan 23, 2019²⁸
VP Marketing & Bus DevelopmentDaniel Philip Gottlieb Oct 21, 2014 to Jan 23, 2019²⁹
Board memberCynthia Smith Feb 1, 2021 to now³⁰
Board memberJane Huang Jun 10, 2021 to now³¹
Board memberGregory Sargen Jan 13, 2020 to now³²
Board memberJesse Shefferman Jan 13, 2020 to now¹⁵
Board memberLuke M. Beshar Jan 13, 2020 to now³³
Board memberMichael Edward Solomon Jan 13, 2020 to now³⁴
Board memberRoger Garceau Jan 13, 2020 to now³⁵
Board memberScott Braunstein Jan 13, 2020 to Jun 11, 2020³⁶
Board memberBarry P. Flannelly Jul 27, 2020 to now³⁷
Board memberJonathan S. Leff Aug 4, 2017 to Jun 12, 2018³⁸
Board memberPaul J. Hastings Oct 20, 2016 to Jun 11, 2018³⁹
Board memberScott A. Canute Jul 23, 2015 to Jun 11, 2018⁴⁰
Board memberStuart A. Kingsley Oct 19, 2015 to Jun 11, 2018⁴¹
Board memberDmitry Kobyzev Oct 21, 2014 to Jun 3, 2015⁴²
Board memberGaren G. Bohlin Oct 21, 2014 to Jun 11, 2018⁴³
Board memberGregory D. Phelps Oct 21, 2014 to Jun 3, 2015⁴⁴
Board memberHubert Birner Oct 21, 2014 to Jun 11, 2018⁴⁵
Board memberJohn Gordon Freund Oct 21, 2014 to Nov 12, 2019⁴⁶
Board memberTimothy Haines Oct 21, 2014 to Jun 11, 2018⁴⁷
Board memberTimothy P. Noyes Oct 21, 2014 to Feb 4, 2019¹⁶
Board memberBrendan O'Leary Oct 22, 2014 to Jun 14, 2016⁴⁸

Former names

Protara Therapeutics, Inc.May 13, 2020 to Aug 13, 2026⁵
ArTara Therapeutics, Inc.Nov 29, 2019 to Apr 23, 2020⁵
PROTEON THERAPEUTICS INCApr 14, 2006 to Dec 31, 2019⁵

Timeline

Jan 13, 2020New chief executive Jesse Shefferman becomes CEO¹⁵
Oct 21, 2014New chief executive Timothy P. Noyes becomes CEO¹⁶
Jan 1, 2001Founded Founded¹

Filings

307 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 48 major events, 149 insider forms, 33 large holders, 57 other. The latest 20:

Aug 13, 2026SCHEDULE 13G/A EDGAR
Aug 11, 2026S-8 REGISTRATION STATEMENT EDGAR
Aug 11, 202610-Q QUARTERLY REPORT EDGAR
Aug 11, 20268-K CURRENT REPORT EDGAR
Jul 7, 2026SCHEDULE 13G/A EDGAR
Jul 1, 20264 PRIMARY DOCUMENT EDGAR
Jun 29, 2026144 EDGAR
Jun 29, 20268-K CURRENT REPORT EDGAR
Jun 16, 20264 PRIMARY DOCUMENT EDGAR
Jun 16, 20264 PRIMARY DOCUMENT EDGAR
Jun 16, 20264 PRIMARY DOCUMENT EDGAR
Jun 16, 20264 PRIMARY DOCUMENT EDGAR
Jun 16, 20264 PRIMARY DOCUMENT EDGAR
Jun 16, 20264 PRIMARY DOCUMENT EDGAR
Jun 16, 20264 PRIMARY DOCUMENT EDGAR
Jun 16, 20264 PRIMARY DOCUMENT EDGAR
Jun 15, 20268-K CURRENT REPORT EDGAR
Jun 3, 20264 PRIMARY DOCUMENT EDGAR
May 28, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
May 22, 2026EFFECT EDGAR

The 307 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 33 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Jupiter Topco LLC	4,696,709	$17.9M	0.0%	New
BlackRock, Inc.	3,663,499	$14.0M	0.0%	+268,531
Millennium Management LLC	3,101,166	$11.8M	0.0%	+269,958
Velan Capital Investment Management LP	2,844,652	$10.9M	6.7%	+10,000
Vanguard Capital Management LLC	2,300,133	$8.8M	0.0%	+181,115
Blackstone Inc.	2,265,514	$8.7M	0.0%	No change
Orbimed Advisors LLC	2,220,000	$8.5M	0.2%	New
Sio Capital Management, LLC	1,921,872	$7.3M	1.3%	−47,967
Acorn Capital Advisors, LLC	1,752,115	$6.7M	1.8%	No change
Integral Health Asset Management, LLC	1,500,000	$5.7M	0.2%	−250,000
5AM Venture Management, LLC	1,369,782	$5.2M	1.8%	No change
Geode Capital Management, LLC	1,326,246	$5.1M	0.0%	+149,046
Citadel Advisors LLC	1,232,365	$4.7M	0.0%	+163,807
State Street Corp	1,068,295	$4.1M	0.0%	+63,153
Qube Research & Technologies Ltd	1,045,516	$4.0M	0.0%	+868,512
Balyasny Asset Management L.P.	1,026,691	$3.9M	0.0%	New
Baker Bros. Advisors LP	971,614	$3.7M	0.0%	No change
ADAR1 Capital Management, LLC	940,512	$3.6M	0.2%	No change
Bank Of America Corp /de/	882,179	$3.4M	0.0%	−43,739
Marshall Wace, Llp	701,021	$2.7M	0.0%	+650,290
Dimensional Fund Advisors LP	683,230	$2.6M	0.0%	+151,963
Northern Trust Corp	552,306	$2.1M	0.0%	+177,454
Point72 Asset Management, L.P.	548,932	$2.1M	0.0%	−603,782
Goldman Sachs Group Inc	546,227	$2.1M	0.0%	+148,246
Catalio Capital Management, LP	520,148	$2.0M	0.4%	−59,876

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataProteon Therapeutics on Wikidata
2
SEC EDGARProteon Therapeutics filings on SEC EDGAR
3
WikipediaProteon Therapeutics on Wikipedia
4
Company websiteProteon Therapeutics logo
5
SEC EDGARProteon Therapeutics filings on SEC EDGAR
6
WikipediaProteon Therapeutics on Wikipedia (revision used)
7
SEC EDGARProteon Therapeutics 10-K for fiscal 2019
8
SEC EDGARProteon Therapeutics 10-K for fiscal 2020
9
SEC EDGARProteon Therapeutics 10-K for fiscal 2021
10
SEC EDGARProteon Therapeutics 10-K for fiscal 2022
11
SEC EDGARProteon Therapeutics 10-K for fiscal 2023
12
SEC EDGARProteon Therapeutics 10-K for fiscal 2024
13
SEC EDGARProteon Therapeutics 10-Q for fiscal 2026
14
SEC EDGARProteon Therapeutics 10-Q for fiscal 2026
15
SEC EDGARJesse Shefferman, Chief executive officer
16
SEC EDGARTimothy P. Noyes, Chief executive officer
17
SEC EDGARPatrick Fabbio, Chief financial officer
18
SEC EDGARBlaine Davis, Chief financial officer
19
SEC EDGARLeonardo Viana Nicacio, Chief Medical Officer
20
SEC EDGARWilliam Conkling, Chief Commercial Officer
21
SEC EDGARJathin Bandari, Chief Medical Officer
22
SEC EDGARHannah Fry, VP, Controller
23
SEC EDGARMartin Sebastian Olivo, Chief Medical Officer
24
SEC EDGARJacqueline Zummo, Sr. Vice President, Research
25
SEC EDGARJulio Casoy, Chief Medical Officer
26
SEC EDGARBradley J. Hartman, VP, People
27
SEC EDGARMatthew Paul Kowalsky, VP, Legal and Secretary
28
SEC EDGARE. Scott Toner, Senior VP of Marketing
29
SEC EDGARDaniel Philip Gottlieb, VP Marketing & Bus Development
30
SEC EDGARCynthia Smith, Board member
31
SEC EDGARJane Huang, Board member
32
SEC EDGARGregory Sargen, Board member
33
SEC EDGARLuke M. Beshar, Board member
34
SEC EDGARMichael Edward Solomon, Board member
35
SEC EDGARRoger Garceau, Board member
36
SEC EDGARScott Braunstein, Board member
37
SEC EDGARBarry P. Flannelly, Board member
38
SEC EDGARJonathan S. Leff, Board member
39
SEC EDGARPaul J. Hastings, Board member
40
SEC EDGARScott A. Canute, Board member
41
SEC EDGARStuart A. Kingsley, Board member
42
SEC EDGARDmitry Kobyzev, Board member
43
SEC EDGARGaren G. Bohlin, Board member
44
SEC EDGARGregory D. Phelps, Board member
45
SEC EDGARHubert Birner, Board member
46
SEC EDGARJohn Gordon Freund, Board member
47
SEC EDGARTimothy Haines, Board member
48
SEC EDGARBrendan O'Leary, Board member